Journal
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
Volume 203, Issue -, Pages 82-88Publisher
ELSEVIER
DOI: 10.1016/j.ejogrb.2016.05.005
Keywords
Vaginal dryness; Sexual function; Vaginal gel; Colostrum; Reproductive age
Categories
Funding
- Bayer-Schering Pharma
- Ely Lilly
- Gedeon-Richter
- HRA Pharma
- Merck Sharpe Dohme
- Novo Nordisk
- Pfizer Inc
- Shionogi Limited
- TEVA/Theramex
- Zambon SpA
Ask authors/readers for more resources
Objective: To prove the efficacy, tolerability and safety of Monurelle Biogel (R) (ZP-025) vaginal gel, which contains a purified, dialyzed, lyophilized bovine colostrum, in women of reproductive age suffering from vaginal dryness. Design: Randomized clinical trial (RCT) (Z7213M01). Setting: Five University Gynaecological Units. Patients: Ninety-five subjects were allocated at random to receive either ZP-025 (n = 48) for about 23 intermenstrual days (1 or 2 times/daily intra-vaginally) or no treatment (lubricants on demand were allowed). Main outcome measures: Change of Verbal Rating Scale (VRS) total and single score for vaginal symptoms, Vaginal Health Index (VHI) score, Female Sexual Function index (FSFI) and Female Sexual Distress Scale-revised (FSDS-R) scores. Results: A total number of 85 subjects was evaluable for primary analyses. Symptoms (VRS) of vaginal discomfort improved significantly already after 11 days, as compared to the control arm (p < 0.0001). The mean VHI score was also significantly higher in ZP-025 group (p < 0.001) at the end of the study.The analysis of covariance with the baseline value as covariate carried out on the FSFI Total Score showed a statistically significant difference in favour of the ZP-025 arm (p < 0.032). A shift from presence to absence of sexual distress (<= 11 points) was more prominent in the ZP-025 arm [10 subjects (40%) in the ZP-025 arm (p < 0.0001) and 6 subjects (21.4%) in the control arm (p = 0.01)]. Women reported a compliance rate of 100% for one ZP-025 application/day. Local tolerability of ZP-025 was excellent or good in 82.9% of the subjects. Conclusions: The present multicentre RCT supports the use of Monurelle Biogel (R) in women of reproductive age reporting symptoms of vaginal dryness. A positive impact on vaginal health and sexual function was also evident. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available